10 years after the UN general assembly special session on drugs
Introduction Pharmacovigilance (PV) systems to monitor drug and vaccine safety are often inadequate in sub-Saharan
Africa. In Malawi, a PV enhancement initiative was introduced to address major barriers to PV.
Objective The objective of this initiative was to improve reporting of adverse events (A...Es) by strengthening passive safety
surveillance via PV training and mentoring of local PV stakeholders and healthcare providers (HCPs) at their own healthcare
facilities (HCFs).
Methods An 18-month PV training and mentoring programme was implemented in collaboration with national stakeholders,
and in partnership with the Ministry of Health, GSK and PATH. Two-day training was provided to Expanded Programme on
Immunisation coordinators, identified as responsible for AE reporting, and four National Regulatory Authority representa-
tives. Abridged PV training and mentoring were provided regularly to HCPs. Support was given in upgrading the national
PV system. Key performance indicators included the number of AEs reported, transmission of AE forms, completeness of
reports, serious AEs reported and timeliness of recording into VigiFlow.
Results In 18 months, 443 HCPs at 61 HCFs were trained. The number of reported AEs increased from 22 (January 2000 to
October 2016) to 228 (November 2016 to May 2018), enabling Malawi to become a member of the World Health Organization
Programme for International Drug Monitoring. Most (98%) AE report forms contained mandatory information on reporter,
event, patient and product, but under 1% were transmitted to the national PV office within 48 h.
Conclusion Regular PV training and mentoring of HCPs were effective in enhancing passive safety surveillance in Malawi,
but the transmission of reports to the national PV centre requires further improvement.
more
Cureus 16(2): e53933. DOI 10.7759/cureus.53933
This publications outlines the specific reproductive health needs of this cadre of adolescents and the programmatic responses that can be used to reach them.
The report presents current information (updated to September 2015) on candidate vaccines, therapies and medical devices for Ebola and gives an overview of completed and on-going trials.
These WHO guidelines which were updated in 2018, are valid for any country and suitable to local adaptations, and take account of the strength of available scientific evidence, the cost and resource implications, and patient values and preferences.
The 2018 edition of the guidelines includes the re...vision of the recommendation regarding the use of 80% fraction of inspired oxygen (high FiO2) in surgical patients under general anaesthesia with tracheal intubation and the update of the section on implementation. Between 2017 and 2018, WHO re-assessed the evidence on the use of high FiO2 by updating the systematic review related to the effectiveness of this intervention to reduce SSI and commissioning an independent systematic review on adverse events potentially associated with it. Based on the updated evidence, the GDG decided to revise the strength of the recommendation from strong to conditional.
more
doi: 10.9745/GHSP-D-16-00226; Glob Health Sci Pract December 23, 2016 vol. 4 no. 4 p. 626-646
The report is based on comprehensive information collected at representative sample health facilities all over the country by well-organized and trained teams during May and August 2015. This is a continuation of 2014 Assessment activities and findings also reflect comparison between two consecutive... years.
more
Otros trastornos
Capítulo H.5.1
Edición: Matías Irarrázaval & Andres Martin
Traductores: Fernanda Prieto-Tagle & Iván Olle Llopis
Psychiatrie de l'enfant
Chapitre B.1
Edition en français
Traduction : Apolline Morville
Sous la direction de : Priscille Gérardin
Avec le soutien de la SFPEADA
Journal of Infection and Public Health 12 (2019) 213–223
Research Article
Journal of Addiction
Volume 2016, Article ID 2476164, 8 pages
http://dx.doi.org/10.1155/2016/2476164
Sudan Medical and Scientific Research Institute, Khartoum, Sudan
Received 26 November 2015; Accepted 27 January 2016